Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis BOriginal Article Published on 2020-10-242023-06-03 Journal: Hepatology international [Category] B형 간염, Fulltext, [키워드] Antiviral Besremi clinical trial HBeAg seroconversion Hepatitis B virus Infectious disease P1101 Pegylated interferon Taiwan therapy [DOI] 10.1007/s12072-020-10098-y PMC 바로가기 [Article Type] Original Article
Clinical Impact Potential of Supplemental Nutrients as Adjuncts of Therapy in High-Risk COVID-19 for Obese PatientsNutrition Published on 2020-10-222022-10-31 Journal: Frontiers in Nutrition [Category] COVID-19, [키워드] acute respiratory syndrome adjunct boost caused China clinical clinical impact clinical trial Comorbidity coronavirus COVID-19 Cytokines disease effective global pandemic Health host immunity Impact Inflammation Intervention management Micronutrient micronutrients nutrient nutrition obese patients Potential reducing SARS-CoV-2 severity of symptom Standard therapy supportive care therapy Treatment viral infections [DOI] 10.3389/fnut.2020.580504 PMC 바로가기 [Article Type] Nutrition
The clinical effect of Nano micelles containing curcumin as a therapeutic supplement in patients with COVID-19 and the immune responses balance changes following treatment: A structured summary of a study protocol for a randomised controlled trialCOVID-19 환자의 치료 보조제로 커큐민을 함유한 나노 미셀의 임상 효과 및 치료 후 면역 반응 균형 변화: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약Letter Published on 2020-10-222022-08-13 Journal: Trials [Category] MERS, SARS, 임상, [키워드] 1:1 accompany addition allergy assigned balance Bandar Abbas bedtime blind Blinding both groups breakfast Capsule change Characteristics chronic chronic obstructive pulmonary disease clinical Clinical effect clinical examination clinical examinations clinical symptom clinical trial clinical trials Comorbidities Comorbidity company comparator Complete computer conducted congestive heart failure control group COVID-19 COVID-19 patient COVID-19 patients Curcumin Cytokines digit digits dinner dissemination Effectiveness element evaluate evaluated expected expression filtration filtration rate FOXP3 gallstone gastritis GATA Gender Gene Expression glomerular filtration rate heart failure history IFN-γ IL-17 IL-4 immune response immune responses in both group inclusion criteria Inflammatory marker inflammatory markers information Interleukins intervention group Iran kPa Laboratory laboratory findings laboratory technician laboratory technicians lactation less liver liver failure Lymphocytes number Nurses objective Obstructive obstructive pulmonary disease outcome PaO2 parallel group participant Participation Patient patients patients with COVID-19 per day performed Peripheral blood physician Placebo placebo group placebo-controlled positive COVID-19 post treatment Pregnancy protocol pulmonary disease random randomisation randomised randomised controlled trial randomization Randomized randomized clinical trial Randomly real time PCR recorded recruitment Registered registry Regulatory renal renal failure routine standard treatment Sample size sealed selected serum cytokine serum cytokines Serum level serum parameter serum parameters shift single-center statisticians Study protocol T helper TGF-β the placebo group therapeutic Treatment Trial Trial registration ventilator Version website written consent [DOI] 10.1186/s13063-020-04824-y PMC 바로가기 [Article Type] Letter
Antiviral Activity of Reagents in Mouth Rinses against SARS-CoV-2SARS-CoV-2에 대한 구강 세정제의 항바이러스 활성Review Published on 2020-10-222022-09-10 Journal: Journal of Dental Research [Category] MERS, 치료제, [키워드] activity aerodigestive tract Antiviral antiviral property capsid Cetylpyridinium cetylpyridinium chloride chlorhexidine chloride Clinical research Clinical studies clinical trial contribute COVID-19 COVID-19 pandemic Critical cyclodextrin denaturing enveloped virus essential oils Evidence examined hydrogen hydrogen peroxide IMPROVE indicate Iodine knowledge leads membrane mouth mouthwashes oral oral cavity pathogenicity povidone povidone-iodine Proteins protocol reagent reagents reduce reducing Research Saliva salivary SARS-CoV-2 transmission of SARS-CoV-2 Viral Viral load virus while [DOI] 10.1177/0022034520967933 PMC 바로가기 [Article Type] Review
Accelerating Clinical Evaluation of Repurposed Combination Therapies for COVID-19Perspective Piece Published on 2020-10-212022-10-28 Journal: The American Journal of Tropical Medicine and Hygi [Category] COVID-19, MERS, SARS, [키워드] absence accelerate accelerated adaptive approach Cell clinical clinical evaluation clinical pharmacology clinical trial Combination combination therapy complementary COVID-19 COVID-19 pandemic detect drug drug combination effective Efficacy facilitated Infectious disease likelihood maintain monotherapy offer pandemic pathophysiology pathway Pharmaceutical interventions Platform trial SARS-CoV-2 second severity supported the disease therapeutic effect therapeutic options treat Treatment Trial [DOI] 10.4269/ajtmh.20-0995 PMC 바로가기 [Article Type] Perspective Piece
The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial중증 코로나바이러스 질환의 치료를 위한 정맥 면역글로불린 감마의 사용 2019: 무작위 위약 대조 이중 맹검 임상 시험Research Article Published on 2020-10-212022-08-13 Journal: BMC Infectious Diseases [Category] MERS, SARS, 임상, [키워드] accompany addition administration assigned clinical Clinical characteristics Clinical outcome clinical trial clinical trials conducted control group coronavirus disease Coronavirus disease 2019 country COVID-19 COVID-19 infection demographics demonstrated disease double-blind effective Efficacy evaluate Immunoglobulin IMPROVE in-hospital mortality in-hospital mortality rate information initial initial treatment initial treatment) initial treatments Intravenous immunoglobulin IVIG Laboratory Laboratory test Laboratory tests medication mortality rate multicenter multivariate regression analysis Occurrence Patient Placebo placebo-controlled Randomized Randomly reduce mortality rate Registered registry required respond Result Sample size severe cases severe coronavirus disease Severe COVID-19 Infection Severe infection significantly significantly lower standard treatment statistically Study protocol subject subjects Treatment two groups were recorded [DOI] 10.1186/s12879-020-05507-4 PMC 바로가기 [Article Type] Research Article
Detailed Molecular Interactions of Favipiravir with SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza Virus Polymerases In SilicoCommunication Published on 2020-10-202022-10-29 Journal: Microorganisms [Category] COVID-19, [키워드] active form active site acute respiratory syndrome antiviral drug clinical trial coronavirus Coronavirus-2 COVID-19 exhibit Favipiravir Genome in silico Infection Influenza influenza A Influenza virus involved ions mechanism MERS-CoV Middle East molecular interaction no interaction nucleotide performed Protein Proteins RdRP replicated Replication respiratory syndrome coronavirus RNA RNA-dependent RNA polymerase SARS-CoV SARS-CoV-2 the SARS-CoV-2 various coronaviruses virus [DOI] 10.3390/microorganisms8101610 PMC 바로가기 [Article Type] Communication
In silico identification of drug candidates against COVID-19Research article Published on 2020-10-202022-10-05 Journal: Informatics in Medicine Unlocked [Category] 신약개발, [키워드] approved drug binding binding affinity binding energy caused clinical trial COVID-19 COVID-19 pandemic disease docked drug candidate drug candidates drug design Drug repurposing effective experiment Health HIV-1 protease inhibitor inhibitor Inhibitory effects ligand-protein docking main protease medication MPro RdRP Remdesivir RNA RNA polymerase RNA-dependent RNA polymerase SARS-CoV-2 main protease SARS-CoV-2 Mpro screened tested therapeutic strategy Treatment Virtual screening [DOI] 10.1016/j.imu.2020.100461 [Article Type] Research article
Proactive prophylaxis with azithromycin and hydroxychloroquine in hospitalized patients with COVID-19 (ProPAC-COVID): a statistical analysis planUpdate Published on 2020-10-202022-10-29 Journal: Trials [Category] COVID-19, MERS, SARS, [키워드] 2019-nCoV age Analysis analyzed antiviral efficacy Azithromycin block chronic lung diseases clinical trial combination therapy data-driven death Detailed statistical analysis plan disease double-blinded evaluate Final hospital Hospital admission Hospitalization hospitalized patient Hydroxychloroquine Infection Infectious diseases intensive care intention-to-treat Intervention ITT ITT analysis modulation non-invasive ventilation outcomes Patient per protocol placebo-controlled Positive test Prevent Primary outcome Prophylaxis randomization Randomized Randomized controlled trial recruitment reduce risk Safety secondary endpoint selective Statistical analysis plan stratified subject symptoms of COVID-19 the patient Treatment Trial with COVID-19 [DOI] 10.1186/s13063-020-04795-0 PMC 바로가기 [Article Type] Update
Integrative Transcriptome Analyses Empower the Anti-COVID-19 Drug ArsenalResearch article Published on 2020-10-192022-10-05 Journal: iScience [Category] 신약개발, 유전자 메커니즘, 치료제, [키워드] acute respiratory syndrome Antiviral approach arsenal bioinformatics candidate caused clinical investigation clinical trial collaborative efforts Combination coronavirus coronavirus disease Corticosteroids COVID-19 dataset datasets drug drug candidate expression profile Janus kinase kinase inhibitors lung monotherapy MOST outbreak outcome pandemic patients with COVID-19 perturbations regimen Remdesivir SARS-CoV-2 Systems biology therapeutic strategy transcriptomes transcriptomic Virology Zoonotic coronavirus [DOI] 10.1016/j.isci.2020.101697 [Article Type] Research article